According to interviewees, additional support would be helpful to high-burden countries with strong health system resources and scientific/ technical capacity. These countries include the BRICS nations (Brazil- Russia- India- China- Republic of South Africa), which make up over half the MDR-TB patients in the world but receive only a little more than a third of the expenditures planned by included projects. India alone receives about 91% of these funds, due to its particular challenges in terms of poverty and health systems capacity. In general, support to these high-burden countries including BRICS and others like Indonesia, Philippines, Pakistan and others would be an investment in existing capacity and has the potential to be an efficient, multiplicative use of resources. By jumpstarting comprehensive MDR-TB care with appropriate drugs, this approach has the potential to reach larger numbers of TB patients in a sustained fashion, according to interviewees, as effective approaches can be continued without development assistance channels in future years.